Zacks.com on MSN6h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Don, a Philadelphia resident, who requested not to share his last name, remembers when he was first diagnosed with HIV in ...
Merced County officials have warned residents of a counterfeit letter claiming to be from the county’s Department of Public ...
Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...
Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback